Movement Alert｜BIOCYTOGEN-B Rises 5.1% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Sustained Institutional Accumulation

Market Focus08-10 09:37

On August 10, BIOCYTOGEN-B rose 5.1% in regular trading, trading at 65.5 HKD/share, with turnover of HKD 29.71 million. The stock continued its upward momentum following a strong performance forecast and persistent institutional buying.

The company recently disclosed its H1 earnings preview, projecting revenue of RMB 936-946 million, representing 51%-52% year-on-year growth, and attributable net profit of RMB 236-246 million, a surge of 392%-413% compared with RMB 48 million in the year-ago period. Notably, Q1 alone delivered RMB 104 million in net profit, marking a turnaround from a prior-year loss.

On the institutional front, E Fund Management raised its long position to 10.0% through multiple purchases at prices ranging from HKD 46.90 to HKD 56.60 per share since June. Fullgoal Fund similarly accumulated shares, lifting its stake to 8.23% following a HKD 28.83 million purchase in late July. The dual-engine growth from animal model services and antibody development, combined with a global bispecific ADC strategic collaboration with Whitehawk Therapeutics covering five antibody candidates, underpins the accelerating profit trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150793115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150793115","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 5.1% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Sustained Institutional Accumulation","media":"Market Focus","content":"<p><p>On August 10, BIOCYTOGEN-B rose 5.1% in regular trading, trading at 65.5 HKD/share, with turnover of HKD 29.71 million. The stock continued its upward momentum following a strong performance forecast and persistent institutional buying.</p><p>The company recently disclosed its H1 earnings preview, projecting revenue of RMB 936-946 million, representing 51%-52% year-on-year growth, and attributable net profit of RMB 236-246 million, a surge of 392%-413% compared with RMB 48 million in the year-ago period. Notably, Q1 alone delivered RMB 104 million in net profit, marking a turnaround from a prior-year loss.</p><p>On the institutional front, E Fund Management raised its long position to 10.0% through multiple purchases at prices ranging from HKD 46.90 to HKD 56.60 per share since June. Fullgoal Fund similarly accumulated shares, lifting its stake to 8.23% following a HKD 28.83 million purchase in late July. The dual-engine growth from animal model services and antibody development, combined with a global bispecific ADC strategic collaboration with Whitehawk Therapeutics covering five antibody candidates, underpins the accelerating profit trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 5.1% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Sustained Institutional Accumulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 5.1% in Regular Trading, H1 Net Profit Expected to Surge Over 4x Amid Sustained Institutional Accumulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, BIOCYTOGEN-B rose 5.1% in regular trading, trading at 65.5 HKD/share, with turnover of HKD 29.71 million. The stock continued its upward momentum following a strong performance forecast and persistent institutional buying.</p><p>The company recently disclosed its H1 earnings preview, projecting revenue of RMB 936-946 million, representing 51%-52% year-on-year growth, and attributable net profit of RMB 236-246 million, a surge of 392%-413% compared with RMB 48 million in the year-ago period. Notably, Q1 alone delivered RMB 104 million in net profit, marking a turnaround from a prior-year loss.</p><p>On the institutional front, E Fund Management raised its long position to 10.0% through multiple purchases at prices ranging from HKD 46.90 to HKD 56.60 per share since June. Fullgoal Fund similarly accumulated shares, lifting its stake to 8.23% following a HKD 28.83 million purchase in late July. The dual-engine growth from animal model services and antibody development, combined with a global bispecific ADC strategic collaboration with Whitehawk Therapeutics covering five antibody candidates, underpins the accelerating profit trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1150793115","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150793115","pubTimestamp":1786325836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, BIOCYTOGEN-B rose 5.1% in regular trading, trading at 65.5 HKD/share, with turnover of HKD 29.71 million. The stock continued its upward momentum following a strong performance forecast...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势预警|BIOCYTOGEN-B常规交易上涨5.1%，机构持续积累下上半年净利有望飙升超4倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 10, BIOCYTOGEN-B rose 5.1% in regular trading, trading at 65.5 HKD/share, with turnover of HKD 29.71 million. The stock continued its upward momentum following a strong performance forecast and persistent institutional buying.The company recently disclosed its H1 earnings preview, projecting revenue of RMB 936-946 million, representing 51%-52% year-on-year growth, and attributable net profit of RMB 236-246 million, a surge of 392%-413% compared with RMB 48 million in the year-ago period. Notably, Q1 alone delivered RMB 104 million in net profit, marking a turnaround from a prior-year loss.On the institutional front, E Fund Management raised its long position to 10.0% through multiple purchases at prices ranging from HKD 46.90 to HKD 56.60 per share since June. Fullgoal Fund similarly accumulated shares, lifting its stake to 8.23% following a HKD 28.83 million purchase in late July. The dual-engine growth from animal model services and antibody development, combined with a global bispecific ADC strategic collaboration with Whitehawk Therapeutics covering five antibody candidates, underpins the accelerating profit trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150793115","isCrawlerRequest":true}